Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials.

EClinicalMedicine · 2022 · PMC9163705 · PMID 35677732

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

a favorable trendp=0.06so close (0.05 < p ≤ 0.1)

There was a favorable trend towards reduced progression to IMV or ECMO (OR 0.76, 95% CI 0.58-1.01; p=0.06, I 2 =49%) in the baricitinib arm compared to standard therapy, even though it was not statistically significant.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.